C4 Therapeutics Income Statement (2019-2026) | CCCC

Income Statement Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Revenue & cost
Revenue (Quarter)
8.50M20.08M7.65M13.83M6.75M2.85M3.76M2.66M11.07M3.26M3.04M12.01M15.36M5.18M7.24M6.46M11.23M11.02M6.15M6.64M
Operating items
Research & Development (Quarter)
24.30M26.55M26.20M31.32M29.66M30.65M29.04M29.93M28.35M30.39M22.53M23.75M31.84M32.51M27.07M26.20M25.99M24.98M24.61M24.47M
Selling, General & Administrative (Quarter)
8.45M8.78M12.82M9.89M9.58M10.49M10.95M10.31M10.53M10.30M10.29M9.70M11.77M10.37M9.33M8.77M8.92M9.18M9.33M8.59M
Other Operating Expenses (Quarter)
2.44M10.73M
Operating Expenses (Quarter)
32.75M35.33M39.02M41.22M39.24M41.15M39.99M40.23M38.88M40.69M35.26M33.45M43.61M42.89M36.40M34.96M45.64M34.16M33.94M33.06M
Operating Income (Quarter)
-24.25M-15.26M-31.37M-27.38M-32.49M-38.29M-36.23M-37.57M-27.81M-37.43M-32.22M-21.44M-28.24M-37.71M-29.16M-28.50M-34.41M-23.14M-27.79M-26.42M
EBIT (Quarter)
-24.25M-15.26M-31.37M-27.38M-32.49M-38.29M-36.23M-37.57M-27.81M-37.43M-32.22M-21.44M-28.24M-37.71M-29.16M-28.50M-34.41M-23.14M-27.79M-26.42M
Non-operating items
Non Operating Investment Income (Quarter)
-0.09M-0.62M-2.88M-0.93M-0.83M1.27M1.67M0.70M0.87M0.78M-0.25M-0.06M0.90M-0.40M-0.01M-0.07M
Interest & Investment Income (Quarter)
0.11M0.14M0.28M0.51M1.08M1.71M2.05M2.25M2.56M2.95M3.86M3.73M3.58M3.27M2.84M2.48M2.25M2.78M2.66M2.79M
Other Non Operating Income (Quarter)
-0.62M
Non Operating Income (Quarter)
-0.43M-0.40M-0.25M-0.03M0.53M1.11M1.45M1.65M1.77M2.95M3.86M3.73M3.58M3.27M2.84M2.48M2.25M2.78M2.66M2.79M
Net income details
EBT (Quarter)
-24.68M-15.66M-31.62M-128.67M-31.96M-37.19M-34.78M-35.92M-26.03M-34.48M-28.36M-17.72M-24.67M-34.44M-26.32M-26.02M-32.17M-20.36M-27.45M-24.08M
Tax Provisions (Quarter)
1.00M0.28M0.13M
Profit After Tax (Quarter)
-24.77M-16.28M-31.62M-27.41M-31.96M-37.21M-34.78M-35.92M-26.17M-30.74M-28.36M-17.72M-23.77M-34.98M-26.32M-26.02M-32.05M-20.49M-25.50M-23.76M
Income from Non-Controlling Interests (Quarter)
0.90M-0.01M0.12M-0.37M-0.12M
Income from Continuing Operations (Quarter)
-24.68M-15.66M-31.62M-128.67M-31.96M-37.19M-34.78M-35.92M-27.04M-34.76M-28.36M-17.72M-24.67M-34.57M-26.32M-26.02M-32.17M-20.36M-27.45M-24.08M
Consolidated Net Income (Quarter)
-24.68M-15.66M-31.62M-128.67M-31.96M-37.19M-34.78M-35.92M-27.04M-34.76M-28.36M-17.72M-24.67M-34.57M-26.32M-26.02M-32.17M-20.36M-27.45M-24.08M
Income towards Parent Company (Quarter)
-24.68M-15.66M-31.62M-128.67M-31.96M-37.19M-34.78M-35.92M-27.04M-34.76M-28.36M-17.72M-24.67M-34.57M-26.32M-26.02M-32.17M-20.36M-27.45M-24.08M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)
-24.68M-15.66M-31.62M-128.67M-31.96M-37.19M-34.78M-35.92M-27.04M-34.76M-28.36M-17.72M-24.67M-34.57M-26.32M-26.02M-32.17M-20.36M-27.45M-24.08M
Additional items
EPS (Basic) (Quarter)
-0.51-0.34-0.65-2.64-0.65-0.76-0.71-0.73-0.55-0.70-0.41-0.26-0.35-0.50-0.37-0.37-0.44-0.25-0.22-0.18
EPS (Diluted) (Quarter)
-0.51-0.34-0.65-2.64-0.65-0.76-0.71-0.73-0.55-0.70-0.41-0.26-0.35-0.50-0.37-0.37-0.44-0.25-0.22-0.18
Shares Outstanding (Quarter)
48.49M46.04M48.73M48.82M48.92M48.86M49.03M49.06M49.21M49.64M68.43M68.81M69.63M69.37M70.83M71.01M72.56M82.89M126.07M130.70M
Shares Outstanding (Diluted) (Quarter)
48.49M46.04M48.73M48.82M48.92M48.86M49.03M49.06M49.21M49.64M68.43M68.81M69.63M69.37M70.83M71.01M72.56M82.89M126.07M130.70M
Shares Outstanding (Entity) (Quarter)
48.59M48.69M48.75M48.88M48.95M48.97M49.05M49.07M49.26M49.64M68.78M68.82M70.56M70.63M70.99M71.01M74.17M96.91M104.04M122.91M
EBITDA (Quarter)
-24.25M-15.26M-31.37M-27.38M-32.49M-38.29M-36.23M-37.57M-27.81M-37.43M-32.22M-21.44M-28.24M-37.71M-29.16M-28.50M-34.41M-23.14M-27.79M-26.42M
Interest Expenses (Quarter)
16.63M0.24M103.88M101.79M99.70M-3.46M2.48M1.79M0.91M-5.43M2.18M0.45M0.04M-6.61M2.25M0.08M0.01M0.06M2.32M0.45M
Tax Rate (Quarter)
-3.85%-0.81%-0.38%